You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

Poster Presentation
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to July 2025

AbstractFullPdf
Dec 2019020
Jan 2020020
Feb 2020010
Mar 2020020
May 2020080
Jun 20200160
Jul 2020071
Aug 2020030
Sep 2020071
Oct 2020052
Nov 20200102
Dec 2020093
Jan 20210112
Feb 2021072
Mar 2021050
Apr 20210152
May 20210161
Jun 20210120
Jul 20210271
Aug 20210513
Sep 202101010
Oct 20210313
Nov 20210173
Dec 2021070
Jan 2022050
Feb 2022042
Mar 2022053
Apr 2022043
May 2022030
Jun 2022031
Jul 2022062
Aug 2022061
Sep 2022030
Oct 2022071
Nov 20220141
Dec 2022041
Jan 2023041
Feb 2023084
Mar 20230134
Apr 2023062
May 2023041
Jun 2023051
Jul 2023051
Aug 2023020
Sep 2023020
Oct 2023043
Nov 2023041
Dec 2023091
Jan 2024031
Feb 2024060
Mar 2024091
Apr 2024064
May 2024080
Jun 2024092
Jul 2024042
Aug 2024050
Sep 2024041
Oct 2024063
Nov 20240111
Dec 2024052
Jan 2025072
Feb 2025034
Mar 2025050
Apr 20250171
May 20250513
Jun 2025084
Jul 2025000
Total0623101